Company Description
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination.
It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose.
In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services.
Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 15, 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 900 |
| CEO | Joseph Papa |
Contact Details
Address: 300 Professional Drive, Suite 400 Gaithersburg, Maryland 20879 United States | |
| Phone | 240 631 3200 |
| Website | emergentbiosolutions.com |
Stock Details
| Ticker Symbol | EBS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001367644 |
| CUSIP Number | 29089Q105 |
| ISIN Number | US29089Q1058 |
| Employer ID | 14-1902018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph C. Papa Jr., M.B.A., R.Ph. | Chief Executive Officer, President and Director |
| Richard S. Lindahl M.B.A. | Executive Vice President and Chief Financial Officer |
| Coleen Glessner | Executive Vice President of Quality, Ethics and Compliance |
| Paul A. Williams | Senior Vice President of Products Business |
| Simon C. Lowry M.D. | Chief Medical Officer and Head of Research and Development |
| Jessica Perl | Senior Vice President, Corporate Secretary and General Counsel |
| Michelle Pepin | Senior Vice President and Chief Human Resource Officer |
| Stephanie Duatschek | Chief Global Strategy and Franchise Development Officer |
| William Hartzel | Senior Vice President of Manufacturing and Bioservices |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2026 | 144 | Filing |
| May 1, 2026 | 144 | Filing |
| May 1, 2026 | 144 | Filing |
| May 1, 2026 | 10-Q | Quarterly Report |
| Apr 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 30, 2026 | 144 | Filing |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 29, 2026 | SCHEDULE 13G | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |